



Published in final edited form as:

Biol Psychiatry. 2020 August 15; 88(4): 294–303. doi:10.1016/j.biopsych.2020.04.002.

Electroencephalography and Event-Related Potential Biomarkers in Individuals at Clinical High Risk for Psychosis

Holly K. Hamilton^{1,2}, Alison Boos^{3,1}, Daniel H. Mathalon^{2,1}

¹San Francisco Veterans Affairs Health Care System, San Francisco, CA

²University of California, San Francisco, San Francisco, CA

³Northern California Institute for Research and Education, San Francisco, CA

Abstract

Clinical outcomes vary among youth at clinical high-risk for psychosis (CHR-P), with approximately 20% progressing to full-blown psychosis over 2–3 years and 30% achieving remission. Recent research efforts have focused on identifying biomarkers that precede psychosis onset and enhance the accuracy of clinical outcome prediction in CHR-P individuals, with the ultimate goal of developing staged treatment approaches based on the individual's level of risk. Identifying such biomarkers may also facilitate progress toward understanding pathogenic mechanisms underlying psychosis onset, which may support the development of mechanistically-informed early interventions for psychosis. In recent years, EEG-based event-related potential (ERP) measures with established sensitivity to schizophrenia have gained traction in the study of CHR-P and its clinical outcomes. In this review, we describe the evidence for ERP abnormalities in CHR-P and discuss how they inform our understanding of information processing deficits as vulnerability markers for emerging psychosis and as indicators of future outcomes. Among the measures studied, P300 and mismatch negativity are notable because deficits predict conversion to psychosis and/or CHR-P remission. However, the accuracy with which these and other measures predict outcomes in CHR-P has been obscured in the prior literature by the tendency to only report group-level differences, underscoring the need for inclusion of individual predictive accuracy metrics in future studies. Nevertheless, both P300 and mismatch negativity show promise as electrophysiological markers of risk for psychosis, as target engagement measures for clinical trials, and as potential translational bridges between human studies and animal models focused on novel drug development for early psychosis.

Corresponding Author: Daniel H. Mathalon, PhD, MD, Department of Psychiatry, University of California, San Francisco, San Francisco, CA, daniel.mathalon@ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures

Dr. Hamilton and Ms. Boos report no biomedical financial interests or potential conflicts of interest. Dr. Mathalon is a consultant for Boehringer Ingelheim, Aptinyx, Greenwich Biosciences, and Cadent Therapeutics.

Keywords

clinical high risk for psychosis; schizophrenia; event-related potentials; sensory processing; P300; mismatch negativity

Longer duration of untreated psychosis in schizophrenia is associated with poorer treatment response and increased likelihood of decline in cognitive, occupational, and/or social functioning. These observations have motivated research efforts to improve early detection of psychosis and identify individuals with putatively prodromal symptoms who are at increased risk for a psychotic disorder, with the ultimate goal of developing early interventions that yield improved clinical outcomes, including the possibility of psychosis prevention. Success of early intervention and prevention approaches ultimately depends on accurate assessment of psychosis risk. Over the last several decades, clinical diagnostic criteria have been developed and validated that prospectively identify individuals with putatively prodromal symptoms, also referred to as the “clinical high-risk for psychosis” (CHR-P) state, “at-risk mental state,” or “psychosis risk syndrome” (1). These criteria generally include the presence of attenuated positive symptoms, brief intermittent psychosis symptoms, and/or recent functional deterioration within the context of genetic risk for psychosis.

Although the validity of CHR-P criteria for predicting future psychosis transition has been repeatedly demonstrated (2), clinical outcomes vary substantially among CHR-P individuals. Approximately 15–29% of CHR-P individuals progress to full psychosis over 2–3 years (2–4), whereas 30% achieve symptom remission and are presumably no longer at risk (4). While algorithms predicting these outcomes using clinical and cognitive data have been developed and validated (5,6), they are not yet sufficiently accurate to support major treatment decisions such as whether antipsychotic medication should be initiated. Accordingly, recent research efforts have focused on identifying biomarkers that precede psychosis onset and improve the accuracy of predictions about future clinical outcomes. Identification of such biomarkers may also elucidate pathogenic mechanisms underlying psychosis onset, which in turn may guide the development of more mechanistically-informed interventions.

Electroencephalography (EEG)-based measures, and event-related potentials (ERP) in particular, have several characteristics that make them suitable as biomarkers of psychosis risk. ERPs are scalp-recorded voltage fluctuations in the EEG time-locked to stimuli or responses that become evident after averaging over repeated trials. Typically originating from post-synaptic potentials in cortical pyramidal neurons, ERPs result from ion flow across the cell membrane in response to neurotransmitters binding with receptors on the post-synaptic cell. When post-synaptic potentials across similarly oriented neurons occur simultaneously, the field potentials summate and resulting voltage is detected on the scalp. ERPs have high temporal resolution, with sensitivity to transient changes in neural activity over tens or hundreds of milliseconds, allowing for tracking of information processing from early sensory and perceptual stages to later higher-order cognitive processes. Accordingly,

ERPs are well-positioned to detect the physiological consequences of abnormalities in neurotransmission that characterize schizophrenia.

Another advantage of ERPs as potential biomarkers is that several ERP components can be recorded during tasks requiring minimal attention, thereby avoiding the pitfalls of measuring brain activity during complex tasks psychiatric patients may struggle to perform due to cognitive/motivational deficits. Furthermore, with respect to preclinical studies, human ERPs are directly translatable to non-human electrophysiology; animal models of ERP paradigms are sensitive to pharmacological and genetic manipulations relevant to psychosis. For these reasons, ERPs have gained traction in the study of schizophrenia and CHR-P individuals as markers of illness progression and as measures of target engagement for drug development studies.

Several ERP components reliably shown to be deficient in schizophrenia have been the focus of ERP studies aimed at developing risk biomarkers in CHR-P. Here, we review the available evidence for ERP abnormalities in CHR-P individuals and how these abnormalities inform our understanding of information processing deficits as vulnerability markers for emerging psychosis. Details of studies are provided in the Supplement.

Sensory/perceptual components

N100 is a negative component that peaks approximately 100ms after stimulus onset for auditory stimuli and 150ms for visual stimuli. N100 amplitude is sensitive to stimulus physical features (e.g., intensity, duration, rise time). In studies of psychiatric disorders, N100 is often measured in oddball target detection paradigms in response to infrequent deviant sounds relative to frequent standard sounds, although it can be elicited in the absence of explicit task demands. Regardless of the paradigm, N100 amplitude is reduced among medicated and unmedicated schizophrenia patients (7) and their first-degree relatives (8,9). N100 is followed by P200, a positive-going potential peaking 200ms post-stimulus. While they often covary, P200 and N100 can be distinguished experimentally, topographically, and functionally, so are unlikely to reflect a single neural process. Like N100, P200 reductions have been reported in schizophrenia (10,11).

Several studies have examined auditory N100 amplitude among CHR-P individuals. Three studies have demonstrated reductions relative to healthy controls (HCs) (12–14), although another reported no group differences (15). All three studies demonstrating N100 reductions relative to HC reported no differences from schizophrenia patients. N100 amplitude deficits were also associated with increased severity of symptoms in a combined sample of healthy, CHR-P, and psychotic children (16).

Few studies have examined early visual components in CHR-P. These studies generally suggest that early visual ERPs, including visual N100 (17) and P100 (18), are intact in CHR-P individuals, although one study suggested that motion-induced N2m amplitude and its associated delta frequency oscillatory response is reduced in CHR-P and may predict psychosis conversion (18).

N100 suppression during self-generated vocalization.

Auditory N100 has been used as a readout of the auditory cortical response to self-generated speech sounds during vocalization (19). Normally, the cortical response to self-generated sounds is suppressed relative to when the sounds are passively heard during playback of speech recordings, which has been attributed to an efference copy/corollary discharge mechanism that prepares sensory brain regions to recognize stimuli produced by our own actions. Numerous studies have shown deficient N100 suppression during self-generated speech in schizophrenia patients (9,20–22) and their first-degree relatives (9). Recent studies have shown deficient N100 suppression during vocalization in CHR-P relative to HCs that correlated with unusual thought content severity (22,23).

Sensory gating.

P50, which peaks at the scalp vertex approximately 50ms post-stimulus, is elicited during a sensory gating paradigm in response to pairs of auditory stimuli separated by a 500ms interstimulus interval. Normally, P50 is larger after the first stimulus (S1) than the second stimulus (S2). The S1 response is thought to reflect the capacity to register an initial auditory stimulus, while the relatively suppressed S2 response reflects gating-out of irrelevant sensory information in order to protect processing of S1 (24). Using paired stimulus paradigms, deficits in sensory gating (i.e., deficient suppression of the response to S2 relative to S1; S2:S1 ratio or S1–S2 difference) have been shown in schizophrenia patients for P50 (25–27), and less commonly, for N100 and P200 (28–30) in which this suppression effect is also evident. Family studies suggest these abnormalities are heritable (31,32).

Three studies have documented deficient P50 or N100 suppression in CHR-P relative to HC (29,33,34), reporting medium to large effect sizes. Another study found no reductions in P50 or N100 suppression (35), while another reported that P50 and N100 suppression were associated with clinical severity across a combined sample of healthy, CHR-P, and schizophrenia participants (36).

Two studies followed CHR-P individuals longitudinally to examine whether sensory gating impairments are associated with future transition to psychosis. Van Tricht and colleagues (37) reported that baseline N100 suppression difference scores, but not P50 or P200 metrics, differentiated future converters from nonconverters (Cohen's $d=0.62$). While N100 suppression deficits contributed modestly to psychosis prediction, they did not predict time-to-conversion among CHR-P individuals. Others found that P50 and N100 suppression do not differentiate converters from nonconverters, although N100 suppression difference scores were reduced among converters relative to HCs, with nonconverters falling intermediately between them (29).

Mismatch Negativity

Mismatch negativity (MMN) occurs 100–250ms after stimulus onset and is maximal over frontocentral electrodes. It is elicited by discriminable deviant sounds occurring during a series of repeated “standard” sounds (38). MMN reflects automatic feature analysis in the

auditory cortex, referred to as auditory sensory “echoic” memory because of its reliance on representations of what has been “standard” in the recent processing stream in order to detect deviance (38,39). MMN also reflects short-term synaptic plasticity and predictive coding, with MMN signaling a prediction error when a deviant stimulus violates the expectancy that a standard stimulus will recur, which builds over presentations of successive standards (40). MMN is considered preattentive and is elicited automatically when individuals are instructed to engage in an unrelated task (38). Indeed, MMN is largely unaffected by top-down information processing (38), allowing examination of auditory processing dysfunction in schizophrenia without the confounding influence of attentional and motivational deficits (41).

Deficient MMN has been well-documented in schizophrenia (42,43). Some inconsistencies in prior literature may be due to the specific deviant stimulus eliciting the MMN (e.g., duration, frequency, intensity). There is some evidence that duration-deviant MMN (dMMN) may be more sensitive to schizophrenia than frequency-deviant MMN (fMMN; 42,44), particularly among first-episode patients (45), although some studies have not found this effect (44,46).

Evidence of reduced amplitudes in CHR-P suggests that MMN is compromised prior to psychosis onset (36,47–58) ($d_s=0.28-0.88$) although some studies have failed to find such evidence (59–63) ($d_s=0.0-0.32$). In studies that also examined schizophrenia patients, MMN amplitudes in CHR-P individuals were either intermediate between HCs and schizophrenia patients (50,58,60) or similar to those of patients (36,47,52). As in the schizophrenia literature, the extent of the MMN reduction in CHR-P may depend on the eliciting stimulus. The majority of CHR-P studies examined dMMN (36,47–53,55–58), but some reported greater reductions in dMMN than fMMN (53,55,60,64), similar to first-episode schizophrenia (45), while others have reported no differences between deviant types (47,48). One study also reported MMN deficits among CHR-P individuals using a duration +frequency double-deviant stimulus (47), a finding replicated by the North American Prodrome Longitudinal Study (NAPLS; 65).

Several studies have also shown baseline MMN amplitude reductions in future converters relative to nonconverters, reporting generally large effect sizes (47,51,62,64). There are also a couple reports with non-significant effects, or effects in the opposite direction than expected, based on a small number of converters (49,59). Some suggest the conversion effect may be specific to dMMN (64), while others found reduced baseline MMN in CHR-P converters across deviant types (47).

Importantly, there is evidence that smaller baseline MMN predicts shorter time-to-conversion among CHR-P individuals, particularly when using duration+frequency double-deviant MMN amplitudes as the predictor (47,65). Moreover, Kim and colleagues (66) recently showed that dMMN distinguishes future CHR-P remitters from nonremitters ($d=0.72$). Nonremitters had reduced amplitudes at baseline relative to remitters and HCs and MMN predicted later functional recovery (66).

Repetition Positivity.

Recent predictive coding models led to the discovery of the “repetition positivity” (RP), a component elicited by standards that increases with successive standard repetitions, consistent with strengthening of the standard’s memory trace and associated prediction that it will recur (67). While schizophrenia literature is still small and mixed (68,69), a recent NAPLS analysis of the RP showed deficient amplitudes in CHR-P individuals, both for earliest appearing standards and more prominently for late appearing standards within local sequences of repeating standards following each deviant (65). This deficit was worse in CHR-P individuals who transitioned to psychosis, and greater deficits were predictive of shorter time-to-conversion.

P300

P300 is a positive voltage deflection in the stimulus-locked ERP that occurs 300ms post-stimulus, elicited during an oddball target detection task by behaviorally relevant infrequent salient stimuli interspersed among frequent standard stimuli (70). P300 amplitude is thought to reflect controlled attentional resource allocation (70,71), contextual updating of working memory (72), and stimulus salience processing (73). There are two subcomponents of P300 that depend on specific task conditions: P3b is elicited by infrequent target stimuli subjects must respond to (e.g., press a button, count), whereas P3a is elicited by infrequent non-target novel distractor stimuli requiring no response (70). P3b reflects effortful top-down attentional allocation and is maximal over parietal electrodes, while P3a reflects automatic, bottom-up orienting of attention, has a frontocentral scalp maximum, and peaks 25–50ms earlier than P3b (70).

Both target P3b and novelty P3a amplitudes are reduced in schizophrenia, particularly when elicited by auditory stimuli (25,74,75). Amplitude reductions are also evident in patients’ first-degree relatives, consistent with P300 amplitude reduction reflecting genetic risk for schizophrenia (76,77). Some studies have shown that P300 amplitude also fluctuates with clinical state (78,79) and that abnormalities worsen with longer illness duration (80,81).

CHR-P studies of P300 have consistently demonstrated deficient P3b amplitudes to auditory (12,15,82–90) and to a lesser extent, visual (17,83), target oddball stimuli ($d_s=0.49-1.6$). In some studies, the magnitude of deficits in CHR-P individuals and schizophrenia patients has been similar (12,17,83). One study examining change in P300 over time failed to find further decline in P3b amplitude after psychosis onset among converters (91). Fewer studies have examined P3a among CHR-P individuals, but evidence exists for reduced auditory (12,49,50,61,63,82,83) and visual (83,92) amplitudes in response to novel or unattended deviant stimuli ($d_s=0.29-0.76$) (but see (59)).

P300 has also been examined among longitudinally-tracked CHR-P individuals. Several studies suggest auditory target P3b is associated with future psychosis onset, differentiating converters from nonconverters (82,83,88,91), reporting medium to large effect sizes. There is also one report of deficient visual target P3b amplitudes among converters relative to nonconverters (83). Both auditory (82,83,88) and visual (83) target P3b deficits predict shorter time to psychosis onset. Moreover, the NAPLS consortium recently reported that

relatively normal auditory target P3b was associated with future CHR-P remission (82). Although Kim et al. (93) found no baseline target P3b amplitude differences between remitters and nonremitters, target P3b amplitudes predicted improvement in negative and general psychopathology symptoms.

Studies examining whether novelty P3a is associated with psychosis conversion have yielded mixed results. While one group reported that auditory novelty P3a amplitudes predicted both conversion and remission (94), others have not found novelty P3a to differentiate converters from nonconverters (59,82,83) or predict time to psychosis onset when elicited by auditory (82,83) or visual (83) stimuli.

Other Higher-Order Cognitive ERPs

Few studies have examined other higher-order cognitive ERPs in CHR-P. The amplitude of the error-related negativity (ERN), which is a response-locked ERP elicited by commission errors during choice response, is reduced in schizophrenia (95). The only study that examined ERN in CHR-P reported amplitude reductions (96). One CHR-P study has examined the late positive potential (LPP), which reflects emotional reactivity and is typically greater for both pleasant and unpleasant relative to neutral stimuli (97). While schizophrenia patients have generally shown an intact hedonic response and similar LPP amplitudes to HCs (98,99), one study found attenuated LPP to pleasant and unpleasant stimuli in CHR-P individuals (100).

Neural Oscillations

Schizophrenia has been linked to abnormalities in neural oscillations and their synchrony. Resting-state EEG spectral abnormalities in schizophrenia have been reported, including increased delta and theta and decreased alpha power (101,102). CHR-P studies have also identified resting spectral abnormalities that predict psychosis conversion, including increased theta and delta power, either alone (103) or in combination with symptom severity (104,105), and decreased alpha peak frequency (103) (but see (106)).

Schizophrenia is also associated with abnormalities in gamma-band (30–80Hz) oscillations, which have been implicated in sensory registration, cross-modal sensory integration, and higher-order cognitive functions (107). Event-related gamma oscillations are typically quantified by transforming the time-voltage domain EEG signal into the time-frequency domain, yielding measures including total power, evoked power, and phase-locking factor (PLF) or intertrial phase coherence (108,109).

Schizophrenia patients have deficits in both power (110,111) and PLF (109–111) of the early auditory gamma-band response, an obligatory gamma burst evident 50–100ms following an auditory stimulus. Such deficits have been linked to abnormalities in parvalbumin expressing GABAergic interneurons and NMDARs in schizophrenia (112). In addition, gamma oscillations are often measured using the gamma auditory steady-state response (ASSR), an EEG response entrained to click trains (often 500ms or longer) presented at a 40Hz driving frequency. Gamma ASSR power and PLF deficits are the most replicated gamma oscillation abnormalities in schizophrenia (113).

Despite numerous gamma oscillation studies in schizophrenia, few studies have examined gamma oscillations in CHR-P. Tada and colleagues (114) found reduced late-latency gamma ASSR total power and PLF in CHR-P relative to HC that were comparable to deficits in schizophrenia. In contrast, others (63) found normal 40Hz gamma ASSR evoked power and PLF in CHR-P. Finally, Perez and colleagues (115) examined early auditory gamma-band responses to standard tones presented during an oddball task in CHR-P. CHR-P individuals demonstrated reduced gamma evoked power similar to schizophrenia patients and marginally reduced PLF. There were no differences between converters and nonconverters.

Alpha-band (8–12Hz) oscillations coordinate synchronous activity between distributed cortical regions via thalamo-cortical tracts (116) and are prominent during cortical idling. Alpha power is suppressed during effortful cognitive tasks requiring attention, response inhibition, and/or other top-down control functions (107), a phenomenon known as alpha event-related desynchronization (ERD; 117). Thus, alpha-ERD is posited to reflect release from cortical inhibition and engagement of cortical networks during cognitive task performance (116). Oddball tasks show decreases in alpha power during processing of target stimuli (118). Both schizophrenia patients (119) and CHR-P individuals (120–122) demonstrate reduced alpha-ERD to target tones relative to HCs. Recent NAPLS analyses demonstrated that CHR-P converters exhibited reduced alpha-ERD relative to nonconverters and HCs, and that decreased alpha-ERD predicted a shorter time-to-conversion (122).

Discussion

This review highlights emerging evidence that several EEG/ERP biomarkers known to be abnormal in schizophrenia are also abnormal in individuals meeting CHR-P criteria, consistent with these abnormalities preceding the onset of full-blown psychosis. Importantly, P300 (82,83,88,91,94) and MMN (47,51,64,65) have been shown to predict conversion to psychosis in several independent studies. While not yet replicated, studies have shown other ERP deficits to predict conversion, including N100 sensory gating (37), RP memory trace effects (65), and alpha-ERD (122). Other established EEG/ERP abnormalities in schizophrenia, including baseline elevations (123,124) and stimulus-driven reductions in gamma oscillations (113), as well as deficient sensory and higher-order cognitive ERPs, remain understudied in CHR-P individuals.

Predictive accuracy

The accuracy with which EEG/ERP measures predict outcomes in CHR-P has been obscured by a focus on testing differences between groups in prior studies. This underscores the need for future studies to include individual predictive accuracy metrics (e.g., area under the curve, sensitivity/specificity, positive/negative predictive value). Receiver operating characteristic (ROC) curves demonstrate sensitivity and specificity tradeoffs as a test's discrimination threshold is systematically varied. The area under the ROC curve (AUC) summarizes a test's accuracy for classifying individuals as belonging to one of two groups across all possible discrimination thresholds and reflects the percentage of randomly drawn pairs of individuals, one from each group, that a test correctly classifies. Of note, it is possible to transform effect size measures like Cohen's *d* to AUC (125). However, the

accuracy of this estimate depends on the assumptions that the test is normally distributed within each group and that variances are equal between groups (125). Since violations of these assumptions can change the estimated AUC relative to the AUC calculated directly from the data, direct calculation of the AUC is preferable. Furthermore, it is important to recognize that in the sample used to develop a binary classifier, the AUC tends to be inflated due to overfitting; shrinkage of a classifier's predictive accuracy is expected when implemented in an independent cross-validation sample (126), underscoring the importance of cross-validation to realistically assess a classifier's performance. Finally, it should be noted that while the AUC metric treats all classification errors as equally serious, the value of false-positive and false-negative errors will vary depending on the purpose for which the test is being used (127). For example, false positive predictions of future conversion are less tolerable when deciding who should receive antipsychotic medication (i.e., emphasis on specificity) than when deciding who should receive a treatment with more benign side effects (i.e., emphasis on sensitivity). Over the range of EEG/ERP measures being examined, we will likely find evidence of sensitivity and specificity trade-offs that will prove relevant for the specific clinical decision being considered.

Utility of EEG/ERP biomarkers

Although most prior CHR-P studies that tracked clinical outcomes focused on whether EEG/ERP abnormalities predict conversion, a few studies have shown that having relatively normal MMN (66) and P300 (82,94) amplitudes at CHR-P diagnosis predicted future remission. Clinically, treatment planning can potentially benefit from both predictive relationships: those at greatest risk for conversion based on biomarker status may benefit from the most aggressive multimodal interventions, whereas those most likely to remit based on biomarker status may simply require clinical monitoring with minimal intervention. Indeed, one of the potential roles for EEG/ERP markers is to help build staged treatment approaches stratified based on an individual's level of risk. The fact that EEG is relatively inexpensive to acquire, particularly compared with other biomarker domains such as MRI, and the possibility that "turn-key" EEG systems could feasibly be placed in clinical settings as part of a multimodal assessment of individuals presenting with attenuated psychotic symptoms, contribute to ongoing interest in EEG/ERP research aimed at further development and refinement of predictive biomarkers. Moreover, future clinical trials aimed at testing novel medications will benefit from biomarkers that can be used to enrich the CHR-P sample for psychosis risk and/or screen out individuals most likely to remit. EEG/ERP measures reviewed here show some potential to serve in this role, along with other clinical (5), biological (128), and genetic (129) measures.

To date, the EEG/ERP measures showing the most promise for predicting CHR-P outcomes have yielded moderate effect sizes, suggesting they are unlikely to be clinically useful as standalone prognostic tests. However, prior studies have relied on traditional EEG/ERP methods and measures. The potential for alternative preprocessing and measurement approaches to yield EEG/ERP measures with improved predictive accuracy remains largely unexplored; focusing on individual prediction accuracy, rather than group-level statistical significance, can motivate efforts to develop and evaluate such alternative approaches. In addition, it may be that EEG/ERP predictors of outcome work well for only a sub-group of

CHR-P individuals. Future studies should examine variables that may moderate the relationship between EEG/ERP predictors and outcomes, allowing identification of subgroups for whom predictive accuracy is sufficiently strengthened to justify their use. Finally, the potential for EEG/ERP measures to contribute to multivariate algorithms incorporating other biomarker and clinical measures for predicting clinical outcomes remains largely unexplored and warrants greater attention.

EEG/ERP biomarkers sensitive to CHR-P and its clinical outcomes can also provide insight into neuropsychological and neurobiological mechanisms underlying CHR-P symptoms and psychosis onset. Psychologically, both MMN and P300 are elicited by improbable deviant stimuli in streams of standard stimuli and both show greater amplitudes when the deviant stimulus is preceded by longer trains of standard stimuli (67,130), consistent with predictive coding models that posit repetition-driven strengthening of the expectation that a standard will recur along with a larger prediction error signal (amplitude) when the expectation is violated. However, the preattentive nature of MMN and the dependence of P300 on top-down attention, coupled with their distinct latencies and scalp topographies, suggest underlying mechanistic differences between them despite similar dependence on stimulus probabilities and contextually-derived stimulus expectancies. For example, neuroanatomically, MMN generators have been localized to auditory (layer 1; 131) and frontal cortex (132,133), while target P300 has been localized to temporo-parietal junction (134,135), with amplitude deficits potentially implicating compromise of these regions in those at greatest risk. Moreover, MMN generation has been mapped to the theta frequency band in human (136) and animal (131,137) studies, while alterations in delta oscillations are associated with P300 deficits observed in schizophrenia (138), suggesting that distinct neural circuits may be involved in the generation of these ERPs.

Inferences about the neurochemical moderators of EEG/ERP measures come mainly from pharmacological challenge studies. While these studies are limited by the fact that drugs seldom interact with only one neuroreceptor type and produce downstream effects on other neurotransmitter systems, it is noteworthy that NMDAR antagonists have been shown in animal (131,139) and human (140) studies to reduce MMN, while human studies have similarly shown NMDAR antagonists to reduce target P300 (141). Thus, MMN and P300 deficits in CHR-P converters are consistent with hypothesized NMDAR hypofunction as an underlying pathophysiological mechanism in schizophrenia (142,143). Unlike MMN, which seems to show relatively specific mediation by NMDAR neurotransmission, P300 has also been linked to noradrenergic (144), dopaminergic (70), and GABAergic systems (145), as well as serotonin 5-HT_{2A} (146), cholinergic muscarinic (147) and cannabinoid receptors (148,149).

A further advantage of EEG/ERP biomarkers for elucidating neurobiological mechanisms underlying psychosis risk is that many of them, including MMN, P3a, sensory gating of P50 and N100, and resting and stimulus-evoked gamma oscillations, can be recorded in animal models, including rodents (139) and non-human primates (150). The translational bridges afforded by EEG/ERP measures distinguish them from many other biomarker domains, particularly MRI, and motivate ongoing research to refine these measures and establish homologies with similar measures in animals.

Conclusions

Among the EEG/ERP measures studied, P300 and MMN are particularly notable because deficits predict clinical outcomes, including conversion and/or remission. Therefore, P300 and MMN show the greatest promise as electrophysiological markers of risk for psychosis, as target engagement measures for pharmacological studies targeting receptors known to moderate their amplitudes, and as potential translational bridges between human studies and animal models focused on drug development for early psychosis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by Career Development Award 1K2CX001878 from the United States Department of Veterans Affairs Clinical Sciences Research and Development Service to Dr. Hamilton and by National Institute of Mental Health grant UO1MH081944 to Dr. Mathalon. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States government, or the National Institutes of Health.

References

1. McGlashan TH, Walsh BC, Woods SW (2010): The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up. New York: Oxford University Press.
2. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. (2012): Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. *Arch Gen Psychiatry*. 69:220–229. [PubMed: 22393215]
3. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, et al. (2013): Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study. *JAMA Psychiatry*. 70:793–802. [PubMed: 23739772]
4. Addington J, Farris M, Stowkowy J, Santesteban-Echarri O, Metzack P, Kalathil MS (2019): Predictors of Transition to Psychosis in Individuals at Clinical High Risk. *Curr Psychiatry Rep*. 21:39. [PubMed: 31037392]
5. Cannon TD, Yu C, Addington J, Bearden CE, Cadenhead KS, Cornblatt BA, et al. (2016): An Individualized Risk Calculator for Research in Prodromal Psychosis. *Am J Psychiatry*. 173:980–988. [PubMed: 27363508]
6. Fusar-Poli P, Rutigliano G, Stahl D, Davies C, Bonoldi I, Reilly T, et al. (2017): Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. *JAMA Psychiatry*. 74:493–500. [PubMed: 28355424]
7. Rosburg T, Boutros NN, Ford JM (2008): Reduced auditory evoked potential component N100 in schizophrenia--a critical review. *Psychiatry Res*. 161:259–274. [PubMed: 18926573]
8. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, et al. (2008): Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. *Biol Psychiatry*. 64:1051–1059. [PubMed: 18701089]
9. Ford JM, Mathalon DH, Roach BJ, Keedy SK, Reilly JL, Gershon ES, et al. (2013): Neurophysiological evidence of corollary discharge function during vocalization in psychotic patients and their nonpsychotic first-degree relatives. *Schizophr Bull*. 39:1272–1280. [PubMed: 23155183]
10. Roth WT, Goodale J, Pfefferbaum A (1991): Auditory event-related potentials and electrodermal activity in medicated and unmedicated schizophrenics. *Biol Psychiatry*. 29:585–599. [PubMed: 1675890]

11. Salisbury DF, Collins KC, McCarley RW (2010): Reductions in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia. *Schizophr Bull.* 36:991–1000. [PubMed: 19282472]
12. del Re EC, Spencer KM, Oribe N, Mesholam-Gately RI, Goldstein J, Shenton ME, et al. (2015): Clinical high risk and first episode schizophrenia: auditory event-related potentials. *Psychiatry Res.* 231:126–133. [PubMed: 25557063]
13. Gudlowski Y, Ozgurda S, Witthaus H, Gallinat J, Hauser M, Winter C, et al. (2009): Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. *Schizophr Res.* 109:141–147. [PubMed: 19268544]
14. Shin KS, Jung WH, Kim JS, Jang JH, Hwang JY, Chung CK, et al. (2012): Neuromagnetic auditory response and its relation to cortical thickness in ultra-high-risk for psychosis. *Schizophr Res.* 140:93–98. [PubMed: 22759440]
15. Bramon E, Shaikh M, Broome M, Lappin J, Berge D, Day F, et al. (2008): Abnormal P300 in people with high risk of developing psychosis. *Neuroimage.* 41:553–560. [PubMed: 18387827]
16. Gonzalez-Heydrich J, Bosquet Enlow M, D' Angelo E, Seidman LJ, Gumlak S, Kim A, et al. (2015): Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. *Schizophr Res.* 169:340–345. [PubMed: 26549629]
17. Oribe N, Hirano Y, Kanba S, del Re EC, Seidman LJ, Mesholam-Gately R, et al. (2013): Early and late stages of visual processing in individuals in prodromal state and first episode schizophrenia: an ERP study. *Schizophr Res.* 146:95–102. [PubMed: 23433503]
18. Martinez A, Gaspar PA, Hillyard SA, Andersen SK, Lopez-Calderon J, Corcoran CM, et al. (2018): Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications. *Am J Psychiatry.* 175:1243–1254. [PubMed: 30278791]
19. Ford JM, Roach BJ, Mathalon DH (2010): Assessing corollary discharge in humans using noninvasive neurophysiological methods. *Nat Protoc.* 5:1160–1168. [PubMed: 20539291]
20. Ford JM, Mathalon DH, Heinks T, Kalba S, Faustman WO, Roth WT (2001): Neurophysiological evidence of corollary discharge dysfunction in schizophrenia. *Am J Psychiatry.* 158:2069–2071. [PubMed: 11729029]
21. Mathalon DH, Ford JM (2008): Corollary discharge dysfunction in schizophrenia: evidence for an elemental deficit. *Clin EEG Neurosci.* 39:82–86. [PubMed: 18450174]
22. Perez VB, Ford JM, Roach BJ, Loewy RL, Stuart BK, Vinogradov S, et al. (2012): Auditory cortex responsiveness during talking and listening: early illness schizophrenia and patients at clinical high-risk for psychosis. *Schizophr Bull.* 38:1216–1224. [PubMed: 21993915]
23. Mathalon DH, Roach BJ, Ferri JM, Loewy RL, Stuart BK, Perez VB, et al. (2019): Deficient auditory predictive coding during vocalization in the psychosis risk syndrome and in early illness schizophrenia: the final expanded sample. *Psychol Med.* 49:1897–1904. [PubMed: 30249315]
24. Boutros NN, Belger A (1999): Midlatency evoked potentials attenuation and augmentation reflect different aspects of sensory gating. *Biol Psychiatry.* 45:917–922. [PubMed: 10202580]
25. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S (2004): Meta-analysis of the P300 and P50 waveforms in schizophrenia. *Schizophr Res.* 70:315–329. [PubMed: 15329307]
26. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH (2007): A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. *Schizophr Res.* 97:137–151. [PubMed: 17604606]
27. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, et al. (2008): P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. *Psychiatry Res.* 158:226–247. [PubMed: 18187207]
28. Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, et al. (2009): Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. *Schizophr Res.* 113:339–346. [PubMed: 19524407]
29. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, Tendolkar I, Bechdolf A, Pukrop R, et al. (2008): Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. *Biol Psychiatry.* 64:376–384. [PubMed: 18395700]

30. Boutros NN, Korzyukov O, Jansen B, Feingold A, Bell M (2004): Sensory gating deficits during the mid-latency phase of information processing in medicated schizophrenia patients. *Psychiatry Res.* 126:203–215. [PubMed: 15157747]
31. Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, et al. (2007): Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. *Arch Gen Psychiatry.* 64:1242–1250. [PubMed: 17984393]
32. Hall MH, Schulze K, Rijdsdijk F, Picchioni M, Ettinger U, Bramon E, et al. (2006): Heritability and reliability of P300, P50 and duration mismatch negativity. *Behav Genet.* 36:845–857. [PubMed: 16826459]
33. Myles-Worsley M, Ord L, Blailes F, Ngiralmu H, Freedman R (2004): P50 sensory gating in adolescents from a pacific island isolate with elevated risk for schizophrenia. *Biol Psychiatry.* 55:663–667. [PubMed: 15038993]
34. Cadenhead KS, Light GA, Shafer KM, Braff DL (2005): P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. *Biol Psychiatry.* 57:1504–1509. [PubMed: 15953486]
35. Ziermans TB, Schothorst PF, Sprong M, Magnee MJ, van Engeland H, Kemner C (2012): Reduced prepulse inhibition as an early vulnerability marker of the psychosis prodrome in adolescence. *Schizophr Res.* 134:10–15. [PubMed: 22085828]
36. Hsieh MH, Shan JC, Huang WL, Cheng WC, Chiu MJ, Jaw FS, et al. (2012): Auditory event-related potential of subjects with suspected pre-psychotic state and first-episode psychosis. *Schizophr Res.* 140:243–249. [PubMed: 22784684]
37. van Tricht MJ, Nieman DH, Koelman JT, Mensink AJ, Bour LJ, van der Meer JN, et al. (2015): Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. *World J Biol Psychiatry.* 16:12–21. [PubMed: 22730901]
38. Näätänen R, Teder W, Alho K, Lavikainen J (1992): Auditory attention and selective input modulation: A topographical ERP study. *NeuroReport.* 3:493. [PubMed: 1391755]
39. Näätänen R, Jacobsen T, Winkler I (2005): Memory-based or afferent processes in mismatch negativity (MMN): A review of the evidence. *Psychophysiology.* 42:25–32. [PubMed: 15720578]
40. Todd J, Michie PT, Schall U, Ward PB, Catts SV (2012): Mismatch negativity (MMN) reduction in schizophrenia—Impaired prediction-error generation, estimation or salience? *EEG Coherence.* 83:222–231.
41. Mathalon DH, Ford JM (2008): Divergent Approaches Converge on Frontal Lobe Dysfunction in Schizophrenia. *American Journal of Psychiatry.* 165:944–948.
42. Umbricht D, Krljes S (2005): Mismatch negativity in schizophrenia: a meta-analysis. *Schizophrenia Research.* 76:1–23. [PubMed: 15927795]
43. Erickson MA, Ruffle A, Gold JM (2016): A meta-analysis of mismatch negativity in schizophrenia: from clinical risk to disease specificity and progression. *Biological Psychiatry.* 79:980–987. [PubMed: 26444073]
44. Todd J, Michie PT, Schall U, Karayanidis F, Yabe H, Naatanen R (2008): Deviant matters: duration, frequency, and intensity deviants reveal different patterns of mismatch negativity reduction in early and late schizophrenia. *Biol Psychiatry.* 63:58–64. [PubMed: 17585889]
45. Haigh SM, Coffman BA, Salisbury DF (2017): Mismatch Negativity in First-Episode Schizophrenia: A Meta-Analysis. *Clin EEG Neurosci.* 48:3–10. [PubMed: 27170669]
46. Hay RA, Roach BJ, Srihari VH, Woods SW, Ford JM, Mathalon DH (2015): Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. *Biological Psychology.* 105:130–137. [PubMed: 25603283]
47. Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, et al. (2014): Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. *Biol Psychiatry.* 75:459–469. [PubMed: 24050720]
48. Carrion RE, Cornblatt BA, McLaughlin D, Chang J, Aulner AM, Olsen RH, et al. (2015): Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis. *Schizophr Res.* 164:1–7. [PubMed: 25728833]

49. Atkinson RJ, Michie PT, Schall U (2012): Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. *Biol Psychiatry*. 71:98–104. [PubMed: 2200060]
50. Jahshan C, Cadenhead KS, Rissling AJ, Kirihara K, Braff DL, Light GA (2012): Automatic sensory information processing abnormalities across the illness course of schizophrenia. *Psychol Med*. 42:85–97. [PubMed: 21740622]
51. Shaikh M, Valmaggia L, Broome MR, Dutt A, Lappin J, Day F, et al. (2012): Reduced mismatch negativity predates the onset of psychosis. *Schizophr Res*. 134:42–48. [PubMed: 22024244]
52. Solis-Vivanco R, Mondragon-Maya A, Leon-Ortiz P, Rodriguez-Agudelo Y, Cadenhead KS, de la Fuente-Sandoval C (2014): Mismatch Negativity reduction in the left cortical regions in first-episode psychosis and in individuals at ultra-high-risk for psychosis. *Schizophr Res*. 158:58–63. [PubMed: 25064664]
53. Nagai T, Kirihara K, Tada M, Koshiyama D, Koike S, Suga M, et al. (2017): Reduced Mismatch Negativity is Associated with Increased Plasma Level of Glutamate in First-episode Psychosis. *Sci Rep*. 7:2258. [PubMed: 28536477]
54. Lavoie S, Jack BN, Griffiths O, Ando A, Amminger P, Couroupis A, et al. (2018): Impaired mismatch negativity to frequency deviants in individuals at ultra-high risk for psychosis, and preliminary evidence for further impairment with transition to psychosis. *Schizophr Res*. 191:95–100. [PubMed: 29132815]
55. Koshiyama D, Kirihara K, Tada M, Nagai T, Koike S, Suga M, et al. (2017): Duration and frequency mismatch negativity shows no progressive reduction in early stages of psychosis. *Schizophr Res*. 190:32–38. [PubMed: 28314681]
56. Murphy JR, Rawdon C, Kelleher I, Twomey D, Markey PS, Cannon M, et al. (2013): Reduced duration mismatch negativity in adolescents with psychotic symptoms: further evidence for mismatch negativity as a possible biomarker for vulnerability to psychosis. *BMC Psychiatry*. 13:45. [PubMed: 23375130]
57. Pantlin LN, Davalos D (2016): Neurophysiology for Detection of High Risk for Psychosis. *Schizophr Res Treatment*. 2016:2697971.
58. Kim M, Cho KI, Yoon YB, Lee TY, Kwon JS (2017): Aberrant temporal behavior of mismatch negativity generators in schizophrenia patients and subjects at clinical high risk for psychosis. *Clin Neurophysiol*. 128:331–339. [PubMed: 28056388]
59. Atkinson RJ, Fulham WR, Michie PT, Ward PB, Todd J, Stain H, et al. (2017): Electrophysiological, cognitive and clinical profiles of at-risk mental state: The longitudinal Minds in Transition (MinT) study. *PLoS One*. 12:e0171657.
60. Brockhaus-Dumke A, Tendolkar I, Pukrop R, Schultze-Lutter F, Klosterkötter J, Ruhrmann S (2005): Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. *Schizophr Res*. 73:297–310. [PubMed: 15653275]
61. Mondragon-Maya A, Solis-Vivanco R, Leon-Ortiz P, Rodriguez-Agudelo Y, Yanez-Tellez G, Bernal-Hernandez J, et al. (2013): Reduced P3a amplitudes in antipsychotic naive first-episode psychosis patients and individuals at clinical high-risk for psychosis. *J Psychiatr Res*. 47:755–761. [PubMed: 23507048]
62. Higuchi Y, Sumiyoshi T, Seo T, Miyanishi T, Kawasaki Y, Suzuki M (2013): Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. *PLoS One*. 8:e54080.
63. Lepock JR, Ahmed S, Mizrahi R, Gerritsen CJ, Maheandiran M, Drvaric L, et al. (2019): Relationships between cognitive event-related brain potential measures in patients at clinical high risk for psychosis. *Schizophr Res*.
64. Bodatsch M, Ruhrmann S, Wagner M, Müller R, Schultze-Lutter F, Frommann I, et al. (2011): Prediction of psychosis by mismatch negativity. *Biol Psychiatry*. 69:959–966. [PubMed: 21167475]
65. Mathalon DH, Hamilton HK, Bachman PM, Belger A, Carrion RE, Duncan E, et al. (2016): Mismatch negativity and repetition positivity predict transition to psychosis in clinical high risk individuals. *International Journal of Psychophysiology*. 37.

66. Kim M, Lee TH, Yoon YB, Lee TY, Kwon JS (2018): Predicting Remission in Subjects at Clinical High Risk for Psychosis Using Mismatch Negativity. *Schizophr Bull.* 44:575–583. [PubMed: 29036493]
67. Baldeweg T (2006): Repetition effects to sounds: evidence for predictive coding in the auditory system. *Trends Cogn Sci.* 10:93–94. [PubMed: 16460994]
68. Baldeweg T, Hirsch SR (2015): Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: a comparison with bipolar disorder and Alzheimer's disease. *Int J Psychophysiol.* 95:145–155. [PubMed: 24681247]
69. McCleery A, Mathalon DH, Wynn JK, Roach BJ, Helleman GS, Marder SR, et al. (2019): Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm. *Psychol Med.* 49:1195–1206. [PubMed: 30642411]
70. Polich J (2007): Updating P300: an integrative theory of P3a and P3b. *Clin Neurophysiol.* 118:2128–2148. [PubMed: 17573239]
71. Isreal JB, Wickens CD, Donchin E (1980): The dynamics of P300 during dual-task performance. *Prog Brain Res.* 54:416–421. [PubMed: 7220944]
72. Donchin E, Coles M (1988): Is the P300 component a manifestation of context updating? (Commentary on Verleger's critique of the context updating model). *Behavioral and Brain Science.* 11:357–374.
73. Sutton S, Braren M, Zubin J, John ER (1965): Evoked potential correlates of stimulus uncertainty. *Science.* 150:1187–1188. [PubMed: 5852977]
74. Jeon YW, Polich J (2003): Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. *Psychophysiology.* 40:684–701. [PubMed: 14696723]
75. Ford JM (1999): Schizophrenia: the broken P300 and beyond. *Psychophysiology.* 36:667–682. [PubMed: 10554581]
76. Turetsky BI, Dress EM, Braff DL, Calkins ME, Green MF, Greenwood TA, et al. (2015): The utility of P300 as a schizophrenia endophenotype and predictive biomarker: clinical and socio-demographic modulators in COGS-2. *Schizophr Res.* 163:53–62. [PubMed: 25306203]
77. Hall MH, Schulze K, Rijdsdijk F, Kalidindi S, McDonald C, Bramon E, et al. (2009): Are auditory P300 and duration MMN heritable and putative endophenotypes of psychotic bipolar disorder? A Maudsley Bipolar Twin and Family Study. *Psychol Med.* 39:1277–1287. [PubMed: 19250581]
78. Mathalon DH, Ford JM, Pfefferbaum A (2000): Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. *Biol Psychiatry.* 47:434–449. [PubMed: 10704955]
79. Ford JM, Mathalon DH, Marsh L, Faustman WO, Harris D, Hoff AL, et al. (1999): P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia. *Biol Psychiatry.* 46:94–101. [PubMed: 10394478]
80. O'Donnell BF, Faux SF, McCarley RW, Kimble MO, Salisbury DF, Nestor PG, et al. (1995): Increased rate of P300 latency prolongation with age in schizophrenia: Electrophysiological evidence for a neurodegenerative process. *Archives of General Psychiatry.* 52:544–549. [PubMed: 7598630]
81. Mathalon DH, Ford JM, Rosenbloom M, Pfefferbaum A (2000): P300 reduction and prolongation with illness duration in schizophrenia. *Biol Psychiatry.* 47:413–427. [PubMed: 10704953]
82. Hamilton HK, Roach BJ, Bachman PM, Belger A, Carrion RE, Duncan E, et al. (2019): Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. *JAMA Psychiatry.*
83. Hamilton HK, Woods SW, Roach BJ, Llerena K, McGlashan TH, Srihari VH, et al. (2019): Auditory and Visual Oddball Stimulus Processing Deficits in Schizophrenia and the Psychosis Risk Syndrome: Forecasting Psychosis Risk With P300. *Schizophr Bull.* 45:1068–1080. [PubMed: 30753731]
84. Frommann I, Brinkmeyer J, Ruhrmann S, Hack E, Brockhaus-Dumke A, Bechdorf A, et al. (2008): Auditory P300 in individuals clinically at risk for psychosis. *Int J Psychophysiol.* 70:192–205. [PubMed: 18700155]

85. Fusar-Poli P, Crossley N, Woolley J, Carletti F, Perez-Iglesias R, Broome M, et al. (2011): Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: longitudinal MRI-EEG study. *Neuroimage*. 55:320–328. [PubMed: 21129489]
86. Fusar-Poli P, Crossley N, Woolley J, Carletti F, Perez-Iglesias R, Broome M, et al. (2011): White matter alterations related to P300 abnormalities in individuals at high risk for psychosis: an MRI-EEG study. *J Psychiatry Neurosci*. 36:239–248. [PubMed: 21299920]
87. van der Stelt O, Lieberman JA, Belger A (2005): Auditory P300 in high-risk, recent-onset and chronic schizophrenia. *Schizophr Res*. 77:309–320. [PubMed: 15944141]
88. van Tricht MJ, Nieman DH, Koelman JH, van der Meer JN, Bour LJ, de Haan L, et al. (2010): Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. *Biol Psychiatry*. 68:642–648. [PubMed: 20627236]
89. Ozgurda S, Gudlowski Y, Witthaus H, Kawohl W, Uhl I, Hauser M, et al. (2008): Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia. *Schizophr Res*. 105:272–278. [PubMed: 18625546]
90. Kim M, Lee TH, Kim JH, Hong H, Lee TY, Lee Y, et al. (2018): Decomposing P300 into correlates of genetic risk and current symptoms in schizophrenia: An inter-trial variability analysis. *Schizophr Res*. 192:232–239. [PubMed: 28400070]
91. van Tricht MJ, Nieman DH, Koelman JH, Bour LJ, van der Meer JN, van Amelsvoort TA, et al. (2011): Auditory ERP components before and after transition to a first psychotic episode. *Biol Psychol*. 87:350–357. [PubMed: 21536095]
92. Lee SY, Namkoong K, Cho HH, Song DH, An SK (2010): Reduced visual P300 amplitudes in individuals at ultra-high risk for psychosis and first-episode schizophrenia. *Neurosci Lett*. 486:156–160. [PubMed: 20858531]
93. Kim M, Lee TY, Lee S, Kim SN, Kwon JS (2015): Auditory P300 as a predictor of short-term prognosis in subjects at clinical high risk for psychosis. *Schizophr Res*. 165:138–144. [PubMed: 25956629]
94. Tang Y, Wang J, Zhang T, Xu L, Qian Z, Cui H, et al. (2019): P300 as an index of transition to psychosis and of remission: Data from a clinical high risk for psychosis study and review of literature. *Schizophr Res*.
95. Martin EA, McCleery A, Moore MM, Wynn JK, Green MF, Horan WP (2018): ERP indices of performance monitoring and feedback processing in psychosis: A meta-analysis. *Int J Psychophysiol*. 132:365–378. [PubMed: 30102934]
96. Perez VB, Ford JM, Roach BJ, Woods SW, McGlashan TH, Srihari VH, et al. (2012): Error monitoring dysfunction across the illness course of schizophrenia. *J Abnorm Psychol*. 121:372–387. [PubMed: 22060947]
97. Hajcak G, Weinberg A, MacNamara A, Foti D (2011): ERPs and the study of emotion. In: Kappenman ES, Luck SJ, editors. *The Oxford Handbook of Event-Related Potential Components*. Oxford: Oxford University Press.
98. Horan WP, Foti D, Hajcak G, Wynn JK, Green MF (2012): Intact motivated attention in schizophrenia: evidence from event-related potentials. *Schizophr Res*. 135:95–99. [PubMed: 22126898]
99. Horan WP, Wynn JK, Kring AM, Simons RF, Green MF (2010): Electrophysiological correlates of emotional responding in schizophrenia. *J Abnorm Psychol*. 119:18–30. [PubMed: 20141239]
100. Strauss GP, Ruiz I, Visser KH, Crespo LP, Dickinson EK (2018): Diminished Hedonic response in neuroleptic-free youth at ultra high-risk for psychosis. *Schizophr Res Cogn*. 12:1–7. [PubMed: 29928593]
101. Boutros NN, Arfken C, Galderisi S, Warrick J, Pratt G, Iacono W (2008): The status of spectral EEG abnormality as a diagnostic test for schizophrenia. *Schizophr Res*. 99:225–237. [PubMed: 18160260]
102. Newson JJ, Thiagarajan TC (2018): EEG Frequency Bands in Psychiatric Disorders: A Review of Resting State Studies. *Front Hum Neurosci*. 12:521. [PubMed: 30687041]
103. van Tricht MJ, Ruhrmann S, Arns M, Muller R, Bodatsch M, Velthorst E, et al. (2014): Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. *Schizophr Res*. 153:42–47. [PubMed: 24508483]

104. Gschwandtner U, Pflueger MO, Semenin V, Gaggiotti M, Riecher-Rossler A, Fuhr P (2009): EEG: a helpful tool in the prediction of psychosis. *Eur Arch Psychiatry Clin Neurosci.* 259:257–262. [PubMed: 19363667]
105. Zimmermann R, Gschwandtner U, Wilhelm FH, Pflueger MO, Riecher-Rossler A, Fuhr P (2010): EEG spectral power and negative symptoms in at-risk individuals predict transition to psychosis. *Schizophr Res.* 123:208–216. [PubMed: 20850950]
106. Ranlund S, Nottage J, Shaikh M, Dutt A, Constante M, Walshe M, et al. (2014): Resting EEG in psychosis and at-risk populations--a possible endophenotype? *Schizophr Res.* 153:96–102. [PubMed: 24486144]
107. Uhlhaas PJ, Singer W (2010): Abnormal neural oscillations and synchrony in schizophrenia. *Nat Rev Neurosci.* 11:100–113. [PubMed: 20087360]
108. Mathalon DH, Sohal VS (2015): Neural Oscillations and Synchrony in Brain Dysfunction and Neuropsychiatric Disorders: It's About Time. *JAMA Psychiatry.* 72:840–844. [PubMed: 26039190]
109. Roach BJ, Mathalon DH (2008): Event-related EEG time-frequency analysis: an overview of measures and an analysis of early gamma band phase locking in schizophrenia. *Schizophr Bull.* 34:907–926. [PubMed: 18684772]
110. Hall MH, Taylor G, Salisbury DF, Levy DL (2011): Sensory gating event-related potentials and oscillations in schizophrenia patients and their unaffected relatives. *Schizophr Bull.* 37:1187–1199. [PubMed: 20363872]
111. Leicht G, Kirsch V, Giegling I, Karch S, Hantschk I, Moller HJ, et al. (2010): Reduced early auditory evoked gamma-band response in patients with schizophrenia. *Biol Psychiatry.* 67:224–231. [PubMed: 19765689]
112. Gonzalez-Burgos G, Lewis DA (2012): NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. *Schizophr Bull.* 38:950–957. [PubMed: 22355184]
113. Thune H, Recasens M, Uhlhaas PJ (2016): The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia: A Meta-analysis. *JAMA Psychiatry.* 73:1145–1153. [PubMed: 27732692]
114. Tada M, Nagai T, Kirihara K, Koike S, Suga M, Araki T, et al. (2016): Differential Alterations of Auditory Gamma Oscillatory Responses Between Pre-Onset High-Risk Individuals and First-Episode Schizophrenia. *Cereb Cortex.* 26:1027–1035. [PubMed: 25452567]
115. Perez VB, Roach BJ, Woods SW, Srihari VH, McGlashan TH, Ford JM, et al. (2013): Early auditory gamma-band responses in patients at clinical high risk for schizophrenia. *Suppl Clin Neurophysiol.* 62:147–162. [PubMed: 24053038]
116. Klimesch W, Sauseng P, Hanslmayr S (2007): EEG alpha oscillations: the inhibition-timing hypothesis. *Brain Res Rev.* 53:63–88. [PubMed: 16887192]
117. Pfurtscheller G, Stancak A Jr, Neuper C (1996): Event-related synchronization (ERS) in the alpha band--an electrophysiological correlate of cortical idling: a review. *Int J Psychophysiol.* 24:39–46. [PubMed: 8978434]
118. Peng W, Hu Y, Mao Y, Babiloni C (2015): Widespread cortical alpha-ERD accompanying visual oddball target stimuli is frequency but non-modality specific. *Behav Brain Res.* 295:71–77. [PubMed: 25979788]
119. Higashima M, Tsukada T, Nagasawa T, Oka T, Okamoto T, Okamoto Y, et al. (2007): Reduction in event-related alpha attenuation during performance of an auditory oddball task in schizophrenia. *Int J Psychophysiol.* 65:95–102. [PubMed: 17448555]
120. Koh Y, Shin KS, Kim JS, Choi JS, Kang DH, Jang JH, et al. (2011): An MEG study of alpha modulation in patients with schizophrenia and in subjects at high risk of developing psychosis. *Schizophr Res.* 126:36–42. [PubMed: 21036541]
121. Kayser J, Tenke CE, Kroppmann CJ, Alschuler DM, Fekri S, Ben-David S, et al. (2014): Auditory event-related potentials and alpha oscillations in the psychosis prodrome: neuronal generator patterns during a novelty oddball task. *Int J Psychophysiol.* 91:104–120. [PubMed: 24333745]

122. Ramyeed A, Roach BJ, Addington J, Bachman PM, Bearden CE, Belger A, et al. (2019): EEG Alpha Event-Related Desynchronization Deficits Predict Conversion to Psychosis in Individuals With the Psychosis Risk Syndrome. *Biological Psychiatry*. 85:S119.
123. Spencer KM (2011): Baseline gamma power during auditory steady-state stimulation in schizophrenia. *Front Hum Neurosci*. 5:190. [PubMed: 22319485]
124. Gandal MJ, Edgar JC, Klook K, Siegel SJ (2012): Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. *Neuropharmacology*. 62:1504–1518. [PubMed: 21349276]
125. Rice ME, Harris GT (2005): Comparing effect sizes in follow-up studies: ROC Area, Cohen's d, and r. *Law Hum Behav*. 29:615–620. [PubMed: 16254746]
126. Wiggins JS (1973): *Personality and prediction: principles of personality assessment*. Reading, MA: Addison-Wesley.
127. Buchwald AM (1965): Values and the Use of Tests. *J Consult Psychol*. 29:49–54. [PubMed: 14277398]
128. Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, et al. (2015): Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. *Schizophr Bull*. 41:419–428. [PubMed: 25103207]
129. Perkins DO, Lohuis LO, Barbee J, Ford J, Jeffries CD, Addington J, et al. (In Press): The Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High-Risk. *American Journal of Psychiatry*.
130. Squires KC, Wickens C, Squires NK, Donchin E (1976): The effect of stimulus sequence on the waveform of the cortical event-related potential. *Science*. 193:1142–1146. [PubMed: 959831]
131. Lakatos P, O'Connell MN, Barczak A, McGinnis T, Neymotin S, Schroeder CE, et al. (2019): The Thalamocortical Circuit of Auditory Mismatch Negativity. *Biol Psychiatry*.
132. Alho K (1995): Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNm) elicited by sound changes. *Ear Hear*. 16:38–51. [PubMed: 7774768]
133. Molholm S, Martinez A, Ritter W, Javitt DC, Foxe JJ (2005): The neural circuitry of preattentive auditory change-detection: an fMRI study of pitch and duration mismatch negativity generators. *Cereb Cortex*. 15:545–551. [PubMed: 15342438]
134. Halgren E, Marinkovic K, Chauvel P (1998): Generators of the late cognitive potentials in auditory and visual oddball tasks. *Electroencephalography and Clinical Neurophysiology*. 106:156–164. [PubMed: 9741777]
135. Soltani M, Knight RT (2000): Neural origins of the P300. *Crit Rev Neurobiol*. 14:199–224. [PubMed: 12645958]
136. Javitt DC, Shelley A, Ritter W (2000): Associated deficits in mismatch negativity generation and tone matching in schizophrenia. *Clin Neurophysiol*. 111:1733–1737. [PubMed: 11018486]
137. Lee M, Balla A, Sershen H, Sehatpour P, Lakatos P, Javitt DC (2018): Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia. *Neuropsychopharmacology*. 43:571–582. [PubMed: 28816240]
138. Lakatos P, Schroeder CE, Leitman DI, Javitt DC (2013): Predictive suppression of cortical excitability and its deficit in schizophrenia. *J Neurosci*. 33:11692–11702. [PubMed: 23843536]
139. Siegel SJ, Talpos JC, Geyer MA (2013): Animal models and measures of perceptual processing in schizophrenia. *Neurosci Biobehav Rev*. 37:2092–2098. [PubMed: 23867801]
140. Rosburg T, Kreitschmann-Andermahr I (2016): The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis. *Clin Neurophysiol*. 127:1387–1394. [PubMed: 26699665]
141. Schwertner A, Zortea M, Torres FV, Caumo W (2018): Effects of Subanesthetic Ketamine Administration on Visual and Auditory Event-Related Potentials (ERP) in Humans: A Systematic Review. *Front Behav Neurosci*. 12:70. [PubMed: 29713269]
142. Moghaddam B, Javitt D (2012): From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology*. 37:4–15. [PubMed: 21956446]

143. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D (2012): Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia. *Schizophrenia Bulletin*. 38:958–966. [PubMed: 22987851]
144. Nieuwenhuis S, Aston-Jones G, Cohen JD (2005): Decision making, the P3, and the locus coeruleus-norepinephrine system. *Psychol Bull*. 131:510–532. [PubMed: 16060800]
145. Watson TD, Petrakis IL, Edgecombe J, Perrino A, Krystal JH, Mathalon DH (2009): Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission. *Int J Neuropsychopharmacol*. 12:357–370. [PubMed: 18771605]
146. Umbricht D, Vollenweider FX, Schmid L, Grubel C, Skrabo A, Huber T, et al. (2003): Effects of the 5-HT_{2A} agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. *Neuropsychopharmacology*. 28:170–181. [PubMed: 12496954]
147. Brown SB, van der Wee NJ, van Noorden MS, Giltay EJ, Nieuwenhuis S (2015): Noradrenergic and cholinergic modulation of late ERP responses to deviant stimuli. *Psychophysiology*. 52:1620–1631. [PubMed: 26352794]
148. D’Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, et al. (2012): Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Delta(9)-THC in humans. *Neuropsychopharmacology*. 37:1632–1646. [PubMed: 22334121]
149. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM (2008): Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. *Eur Neuropsychopharmacol*. 18:569–577. [PubMed: 18544469]
150. Javitt DC (2015): Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. *Ann N Y Acad Sci*. 1344:92–104. [PubMed: 25721890]